China

Ascletis Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

BIO Digital 2021

Participation Not Confirmed

Update your events

Overweight and Obese Subjects Dosed with ASC41 Tablets in a Phase Ib Trial

Lead Product(s): ASC41

Therapeutic Area: Cardiology/Vascular Diseases Product Name: ASC41

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 22, 2020

Details:

The trial aims to evaluate 1) the impact of ASC41 on markers of cardiac health; 2) the safety and tolerability of ASC41 tablets; 3) the pharmacokinetics of ASC41 tablets and its active moiety, ASC41-A, in overweight and obese subjects.

SHENZHEN SALUBRIS PHARMACEUTICALS CO.LTD.

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

BIO Digital 2021

Participation Not Confirmed

Update your events

Carlyle to Acquire 5% Stake in Salubris, a Leading Biopharmaceutical Company in China

Lead Product(s): JK07

Therapeutic Area: Cardiology/Vascular Diseases Product Name: JK07

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Carlyle

Deal Size: $260.0 million Upfront Cash: Undisclosed

Deal Type: Acquisition September 01, 2020

Details:

Salubris has developed a comprehensive innovative pipeline in the treatment of chronic diseases, including JK07, an innovative biologic drug treating heart failure which has filed for clinical trial approvals in both China and the United States.